Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen
The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with...
Saved in:
| Published in | Journal of neuroimmune pharmacology Vol. 18; no. 4; pp. 551 - 562 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.12.2023
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1557-1890 1557-1904 1557-1904 |
| DOI | 10.1007/s11481-023-10086-7 |
Cover
Loading…
| Abstract | The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with HAND randomized to a less neurotoxic regimen, or continuing their treatment. Adult patients with HAND were screened and enrolled if presenting no major resistance associated mutations, no HIV viral replication, not on efavirenz or darunavir, with R5-tropic HIV and without major confounding conditions. Lumbar puncture, IMT and Fibroscan measurements were performed. After 1:1 randomization to a less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc, or mantaining actual care, tests were repeated after 24 weeks: CSF biomarkes (HIV RNA, tau, p-tau, Beta-amyloid
1-42
, S100Beta and neopterin) were included. Non-parametric tests (Mann–Whitney and Wilcoxon’s) were used. 28 participants completed the study. Male and European ancestry were prevalent; median age was 55 years (51–60). All patients were virally suppressed; median CD4 + count was 626 cell/uL (469–772). Baseline characteristics were similar between the study arms. A significant decrease in CSF p-tau and an increase in CSF neopterin and NFL were observed. We observed a significant reduction in liver stiffness at W24. Despite a small sample size we observed changes in neuromarkers and in hepatic stiffness in patients randomized to the experimental arm. We observed changes in CSF biomarkers (lower phosphorylated-tau and higher neopterin and NFL) that need to be replicated in large cohorts. Subclinical neurotoxicity may be observed in patients with HAND and warrants prospective studies.
Graphical Abstract |
|---|---|
| AbstractList | The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with HAND randomized to a less neurotoxic regimen, or continuing their treatment. Adult patients with HAND were screened and enrolled if presenting no major resistance associated mutations, no HIV viral replication, not on efavirenz or darunavir, with R5-tropic HIV and without major confounding conditions. Lumbar puncture, IMT and Fibroscan measurements were performed. After 1:1 randomization to a less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc, or mantaining actual care, tests were repeated after 24 weeks: CSF biomarkes (HIV RNA, tau, p-tau, Beta-amyloid
1-42
, S100Beta and neopterin) were included. Non-parametric tests (Mann–Whitney and Wilcoxon’s) were used. 28 participants completed the study. Male and European ancestry were prevalent; median age was 55 years (51–60). All patients were virally suppressed; median CD4 + count was 626 cell/uL (469–772). Baseline characteristics were similar between the study arms. A significant decrease in CSF p-tau and an increase in CSF neopterin and NFL were observed. We observed a significant reduction in liver stiffness at W24. Despite a small sample size we observed changes in neuromarkers and in hepatic stiffness in patients randomized to the experimental arm. We observed changes in CSF biomarkers (lower phosphorylated-tau and higher neopterin and NFL) that need to be replicated in large cohorts. Subclinical neurotoxicity may be observed in patients with HAND and warrants prospective studies. The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with HAND randomized to a less neurotoxic regimen, or continuing their treatment. Adult patients with HAND were screened and enrolled if presenting no major resistance associated mutations, no HIV viral replication, not on efavirenz or darunavir, with R5-tropic HIV and without major confounding conditions. Lumbar puncture, IMT and Fibroscan measurements were performed. After 1:1 randomization to a less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc, or mantaining actual care, tests were repeated after 24 weeks: CSF biomarkes (HIV RNA, tau, p-tau, Beta-amyloid 1-42 , S100Beta and neopterin) were included. Non-parametric tests (Mann–Whitney and Wilcoxon’s) were used. 28 participants completed the study. Male and European ancestry were prevalent; median age was 55 years (51–60). All patients were virally suppressed; median CD4 + count was 626 cell/uL (469–772). Baseline characteristics were similar between the study arms. A significant decrease in CSF p-tau and an increase in CSF neopterin and NFL were observed. We observed a significant reduction in liver stiffness at W24. Despite a small sample size we observed changes in neuromarkers and in hepatic stiffness in patients randomized to the experimental arm. We observed changes in CSF biomarkers (lower phosphorylated-tau and higher neopterin and NFL) that need to be replicated in large cohorts. Subclinical neurotoxicity may be observed in patients with HAND and warrants prospective studies. Graphical Abstract The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with HAND randomized to a less neurotoxic regimen, or continuing their treatment. Adult patients with HAND were screened and enrolled if presenting no major resistance associated mutations, no HIV viral replication, not on efavirenz or darunavir, with R5-tropic HIV and without major confounding conditions. Lumbar puncture, IMT and Fibroscan measurements were performed. After 1:1 randomization to a less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc, or mantaining actual care, tests were repeated after 24 weeks: CSF biomarkes (HIV RNA, tau, p-tau, Beta-amyloid , S100Beta and neopterin) were included. Non-parametric tests (Mann-Whitney and Wilcoxon's) were used. 28 participants completed the study. Male and European ancestry were prevalent; median age was 55 years (51-60). All patients were virally suppressed; median CD4 + count was 626 cell/uL (469-772). Baseline characteristics were similar between the study arms. A significant decrease in CSF p-tau and an increase in CSF neopterin and NFL were observed. We observed a significant reduction in liver stiffness at W24. Despite a small sample size we observed changes in neuromarkers and in hepatic stiffness in patients randomized to the experimental arm. We observed changes in CSF biomarkers (lower phosphorylated-tau and higher neopterin and NFL) that need to be replicated in large cohorts. Subclinical neurotoxicity may be observed in patients with HAND and warrants prospective studies. The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with HAND randomized to a less neurotoxic regimen, or continuing their treatment. Adult patients with HAND were screened and enrolled if presenting no major resistance associated mutations, no HIV viral replication, not on efavirenz or darunavir, with R5-tropic HIV and without major confounding conditions. Lumbar puncture, IMT and Fibroscan measurements were performed. After 1:1 randomization to a less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc, or mantaining actual care, tests were repeated after 24 weeks: CSF biomarkes (HIV RNA, tau, p-tau, Beta-amyloid1-42, S100Beta and neopterin) were included. Non-parametric tests (Mann-Whitney and Wilcoxon's) were used. 28 participants completed the study. Male and European ancestry were prevalent; median age was 55 years (51-60). All patients were virally suppressed; median CD4 + count was 626 cell/uL (469-772). Baseline characteristics were similar between the study arms. A significant decrease in CSF p-tau and an increase in CSF neopterin and NFL were observed. We observed a significant reduction in liver stiffness at W24. Despite a small sample size we observed changes in neuromarkers and in hepatic stiffness in patients randomized to the experimental arm. We observed changes in CSF biomarkers (lower phosphorylated-tau and higher neopterin and NFL) that need to be replicated in large cohorts. Subclinical neurotoxicity may be observed in patients with HAND and warrants prospective studies.The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with HAND randomized to a less neurotoxic regimen, or continuing their treatment. Adult patients with HAND were screened and enrolled if presenting no major resistance associated mutations, no HIV viral replication, not on efavirenz or darunavir, with R5-tropic HIV and without major confounding conditions. Lumbar puncture, IMT and Fibroscan measurements were performed. After 1:1 randomization to a less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc, or mantaining actual care, tests were repeated after 24 weeks: CSF biomarkes (HIV RNA, tau, p-tau, Beta-amyloid1-42, S100Beta and neopterin) were included. Non-parametric tests (Mann-Whitney and Wilcoxon's) were used. 28 participants completed the study. Male and European ancestry were prevalent; median age was 55 years (51-60). All patients were virally suppressed; median CD4 + count was 626 cell/uL (469-772). Baseline characteristics were similar between the study arms. A significant decrease in CSF p-tau and an increase in CSF neopterin and NFL were observed. We observed a significant reduction in liver stiffness at W24. Despite a small sample size we observed changes in neuromarkers and in hepatic stiffness in patients randomized to the experimental arm. We observed changes in CSF biomarkers (lower phosphorylated-tau and higher neopterin and NFL) that need to be replicated in large cohorts. Subclinical neurotoxicity may be observed in patients with HAND and warrants prospective studies. The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive disorders is complex and multifactorial. Aim of the study was to measure the change in CSF biomarkers, Fibroscan and IMT measurements in PLWH with HAND randomized to a less neurotoxic regimen, or continuing their treatment. Adult patients with HAND were screened and enrolled if presenting no major resistance associated mutations, no HIV viral replication, not on efavirenz or darunavir, with R5-tropic HIV and without major confounding conditions. Lumbar puncture, IMT and Fibroscan measurements were performed. After 1:1 randomization to a less neurotoxic regimen consisting of darunavir/cobicistat plus emtricitabine plus maraviroc, or mantaining actual care, tests were repeated after 24 weeks: CSF biomarkes (HIV RNA, tau, p-tau, Beta-amyloid1-42, S100Beta and neopterin) were included. Non-parametric tests (Mann–Whitney and Wilcoxon’s) were used. 28 participants completed the study. Male and European ancestry were prevalent; median age was 55 years (51–60). All patients were virally suppressed; median CD4 + count was 626 cell/uL (469–772). Baseline characteristics were similar between the study arms. A significant decrease in CSF p-tau and an increase in CSF neopterin and NFL were observed. We observed a significant reduction in liver stiffness at W24. Despite a small sample size we observed changes in neuromarkers and in hepatic stiffness in patients randomized to the experimental arm. We observed changes in CSF biomarkers (lower phosphorylated-tau and higher neopterin and NFL) that need to be replicated in large cohorts. Subclinical neurotoxicity may be observed in patients with HAND and warrants prospective studies. |
| Author | Barco, Ambra Pirriatore, Veronica Atzori, Cristiana Nigra, Marco Bonora, Stefano Trunfio, Mattia Giaccone, Claudia Calcagno, Andrea Vai, Daniela Stroffolini, Giacomo Di Perri G, Giovanni Lazzaro, Alessandro |
| Author_xml | – sequence: 1 givenname: Giacomo orcidid: 0000-0001-8012-0237 surname: Stroffolini fullname: Stroffolini, Giacomo organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin, Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital – sequence: 2 givenname: Alessandro surname: Lazzaro fullname: Lazzaro, Alessandro organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin, Department of Public Health and Infectious Diseases, Sapienza University of Rome – sequence: 3 givenname: Ambra surname: Barco fullname: Barco, Ambra organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin, Department of Infectious Diseases, Novara Hospital – sequence: 4 givenname: Veronica surname: Pirriatore fullname: Pirriatore, Veronica organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin – sequence: 5 givenname: Daniela surname: Vai fullname: Vai, Daniela organization: Maria Vittoria Hospital, Unit of Neurology, Asl Città di Torino – sequence: 6 givenname: Claudia surname: Giaccone fullname: Giaccone, Claudia organization: Maria Vittoria Hospital, Unit of Neurology, Asl Città di Torino – sequence: 7 givenname: Marco surname: Nigra fullname: Nigra, Marco organization: San Giovanni Bosco Hospital, Laboratory, Asl Città di Torino – sequence: 8 givenname: Cristiana surname: Atzori fullname: Atzori, Cristiana organization: Maria Vittoria Hospital, Laboratory, Asl Città di Torino – sequence: 9 givenname: Mattia surname: Trunfio fullname: Trunfio, Mattia organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin – sequence: 10 givenname: Stefano surname: Bonora fullname: Bonora, Stefano organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin – sequence: 11 givenname: Giovanni surname: Di Perri G fullname: Di Perri G, Giovanni organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin – sequence: 12 givenname: Andrea surname: Calcagno fullname: Calcagno, Andrea email: andrea.calcagno@unito.it organization: Department of Medical Sciences, Infectious Diseases Unit, University of Turin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37906406$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ksuOFCEYhYkZ41z0BVwYEjcuLAWKKqiV0dZxOumomYxuCUXR3cxUQQvUeHkwn8-_uqe9zGJWQDjny4HzH6MDH7xF6DElLygh4mWilEtaEFYWcJZ1Ie6hI1pVoqAN4Qf7vWzIITpO6ZIQzjkhD9BhKRpSc1IfoV-ztfYrm7DzeGajbWNIG-d1j0_70XXP8cJd24i17_DcZzfoYrCd00VeO3PlbUr4jQuDjlc2bhmfdHbW54S_ubzGZ_MvhU4pGKez7fAHO8Zgwsq7DFT81qUQu8l4DvwwuJ-gyQFrvJjAW3UO353BF9HqPAAXn9uVg81DdH-p-2Qf3awn6PPpu4vZWbH4-H4-e70oDBdVLphmRFjWLOtlWwoqq66mkld1x3VHW6NLU5Ytk0vTdqxuWtNIydsGPtRKU7e8LE_Qqx13M7bwcAMRou7VJsJPxB8qaKf-v_FurVbhWlEiBGFMAOHZDSGGr6NNWQ0uGdv32tswJsWkrBhh0BJIn96SXoYxQhegagBIG1HXoHryb6Q_WfadgkDuBAa6TNEulXEZaglTQtdDNDWNj9qNj4LXqu34qCksu2Xd0-80lTtTAjHMUvwb-w7Xb_Me2yY |
| CitedBy_id | crossref_primary_10_1093_brain_awae271 |
| Cites_doi | 10.1093/jac/dky212 10.1097/QAI.0000000000001936 10.1016/j.lfs.2019.116851 10.1212/WNL.0000000000007767 10.1097/QAD.0000000000002597 10.1007/s13365-012-0120-3 10.1016/j.metabol.2017.04.005 10.1007/s11904-018-0375-2 10.1136/bmjopen-2019-035596 10.1371/journal.pone.0251944 10.1212/01.WNL.0000287431.88658.8b 10.1212/WNL.0b013e31821670fb 10.1007/s13365-016-0490-z 10.1007/s13365-015-0416-1 10.1097/QAD.0000000000002601 10.1097/QAI.0000000000003184 10.1038/srep28853 10.1002/dad2.12069 10.1007/s13365-015-0371-x 10.1007/s13365-021-01047-y 10.3851/IMP3140 10.3390/ijms15034671 10.1097/QAD.0000000000002121 10.1093/jac/dkv037 10.3390/v14040753 10.1007/s10461-017-1683-z 10.7448/IAS.17.4.19643 10.1097/QAI.0000000000000957 10.1111/hiv.12828 10.1016/j.ebiom.2015.11.036 10.1371/journal.pone.0157160 10.1097/QAD.0000000000002806 10.1007/s13365-018-0664-y 10.1007/s13365-020-00874-9 10.1007/s13365-013-0181-y 10.1007/s13365-017-0587-z 10.1093/ofid/ofz112 10.1097/QAI.0b013e3181f5b3d1 10.1038/nrneurol.2015.248 10.1007/s13365-014-0279-x 10.1038/s41598-022-10474-8 10.7448/IAS.17.4.19722 10.3389/fnagi.2019.00187 10.1097/QAD.0000000000000951 10.1007/7854_2019_116 10.1111/hiv.12622 10.1310/hct1304-222 10.1097/QAD.0000000000000538 10.1097/QAD.0000000000000074 10.1093/gerona/glq066 10.1371/journal.pone.0052720 10.1093/jac/dkr427 10.1016/S1474-4422(14)70137-1 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2023. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2023. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s11481-023-10086-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1557-1904 |
| EndPage | 562 |
| ExternalDocumentID | PMC10770227 37906406 10_1007_s11481_023_10086_7 |
| Genre | Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: This work was partly supported by the Italian Ministry of Health “Fondi Ricerca Corrente” to IRCCS Sacro Cuore Don Calabria Hospital |
| GroupedDBID | --- -56 -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29L 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5VS 67N 67Z 6NX 7X7 88E 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHQN ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACSNA ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFGCZ AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HLICF HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ ITM IWAJR IXC IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LLZTM M1P M4Y MA- MK0 N2Q NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM PF0 PQQKQ PROAC PSQYO PT4 QOR QOS R89 R9I ROL RPX RSV S16 S1Z S27 S3A S3B SAP SBL SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z87 ZMTXR ZOVNA ~A9 ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c475t-2a207e29f6fb37185d618456d4ad1bca3c33b28fcbd269bc9884b9023e8c6b433 |
| IEDL.DBID | U2A |
| ISSN | 1557-1890 1557-1904 |
| IngestDate | Thu Aug 21 18:42:19 EDT 2025 Fri Jul 11 01:39:42 EDT 2025 Sat Aug 23 13:34:09 EDT 2025 Mon Jul 21 05:56:49 EDT 2025 Thu Apr 24 23:11:08 EDT 2025 Tue Jul 01 00:22:31 EDT 2025 Fri Feb 21 02:44:18 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | PLWH Non-invasive tools Neurovirology Neuromarkers HAND |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c475t-2a207e29f6fb37185d618456d4ad1bca3c33b28fcbd269bc9884b9023e8c6b433 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0001-8012-0237 |
| OpenAccessLink | https://link.springer.com/10.1007/s11481-023-10086-7 |
| PMID | 37906406 |
| PQID | 2910719766 |
| PQPubID | 2045886 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10770227 proquest_miscellaneous_2885202189 proquest_journals_2910719766 pubmed_primary_37906406 crossref_citationtrail_10_1007_s11481_023_10086_7 crossref_primary_10_1007_s11481_023_10086_7 springer_journals_10_1007_s11481_023_10086_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-01 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Journal of neuroimmune pharmacology |
| PublicationTitleAbbrev | J Neuroimmune Pharmacol |
| PublicationTitleAlternate | J Neuroimmune Pharmacol |
| PublicationYear | 2023 |
| Publisher | Springer US Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer Nature B.V |
| References | VassalloMDunaisBDurantJRelevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt studyJ Neurovirol20131943763821:CAS:528:DC%2BC3sXhsVSisb%2FK10.1007/s13365-013-0181-y23846287 Pérez-Valero I, Pasquau J, Rubio R et al (2018) GESIDA 7011 Study Group members. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. J Antimicrob Chemother 73(9):2444–2451. https://doi.org/10.1093/jac/dky212 RobertsonKLinerJMeekerRBAntiretroviral neurotoxicityJ Neurovirol20121853883991:CAS:528:DC%2BC38XhsVyiu7fM10.1007/s13365-012-0120-3228112643581315 AndersonAMEasleyKAKasherNNeurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapyJ Neurovirol20182466957011:CAS:528:DC%2BC1cXhsFSqtLbF10.1007/s13365-018-0664-y301055026279552 Trunfio M, Atzori C, Pasquero M et al (2022) Patterns of cerebrospinal fluid alzheimer's dementia biomarkers in people living with HIV: cross-sectional study on associated factors according to viral control, neurological confounders and neurocognition. Viruses 14(4):753. https://doi.org/10.3390/v14040753 Bradshaw D, Gilleece Y, Verma S, Abramowicz I, Bremner S, Perry N (2020) Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. BMJ Open 10(7):e035596. https://doi.org/10.1136/bmjopen-2019-035596 Lemoine M, Assoumou L, De Wit S et al (2019) ANRS-ECHAM Group. Diagnostic accuracy of noninvasive markers of steatosis, nash, and liver fibrosis in hiv-monoinfected individuals at risk of nonalcoholic fatty liver disease (nafld): results from the echam study. J Acquir Immune Defic Syndr 80(4):e86-e94. https://doi.org/10.1097/QAI.0000000000001936 MsokaTFVan GuilderGPvan FurthMThe effect of HIV infection, antiretroviral therapy on carotid intima-media thickness: A systematic review and meta-analysisLife Sci2019152351:CAS:528:DC%2BC1MXhslGmsLrN10.1016/j.lfs.2019.116851 SacktorNSkolaskyRLMoxleyRParoxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trialJ Neurovirol201824116271:CAS:528:DC%2BC2sXhslWjurjE10.1007/s13365-017-0587-z29063516 Trunfio M, Rugge W, Mighetto L et al (2020) Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. AIDS 34(13):1899–1906. https://doi.org/10.1097/QAD.0000000000002601 MondiAFabbianiMCiccarelliNEfficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot studyJ Antimicrob Chemother2015706184318491:CAS:528:DC%2BC2MXhsFaiu7bP10.1093/jac/dkv03725885326 Mietelska-Porowska A, Wasik U, Goras M et al (2014) Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci 15(3):4671–713. https://doi.org/10.3390/ijms15034671 PiconiSPocaterraDRainoneVMaraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected PatientsSci Rep2016296288531:CAS:528:DC%2BC28XhtFSqt77E10.1038/srep28853 De BenedettoITrunfioMGuastamacchiaGBonoraSCalcagnoAA review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugsJ Neurovirol202026564265110.1007/s13365-020-00874-932737860 Yu X, Kuo YF, Raji MA et al (2023) Dementias Among Older Males and Females in the U.S. Medicare System With and Without HIV. J Acquir Immune Defic Syndr 93(2):107–115. https://doi.org/10.1097/QAI.0000000000003184 AntinoriAArendtGBeckerJTUpdated research nosology for HIV-associated neurocognitive disordersNeurology20076918178917991:STN:280:DC%2BD2snktFyqsQ%3D%3D10.1212/01.WNL.0000287431.88658.8b17914061 Bobrow K, Xia F, Hoang T, Valcour V, Yaffe K (2020) HIV and risk of dementia in older veterans. AIDS 34(11):1673–1679. https://doi.org/10.1097/QAD.0000000000002597 Francisci D, Pirro M, Schiaroli E et al (2019) Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study. Open Forum Infect Dis 6(4):ofz112. https://doi.org/10.1093/ofid/ofz112 NightingaleSWinstonALetendreSControversies in HIV-associated neurocognitive disordersLancet Neurol20141311113911511:CAS:528:DC%2BC2cXhslGrs7nK10.1016/S1474-4422(14)70137-1253160204313542 Gates TM, Cysique LA, Siefried KJ et al (2016) Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS 30(4):591–600. https://doi.org/10.1097/QAD.0000000000000951 NdhlovuLCUmakiTChewGMTreatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)J Neurovirol20142065715821:CAS:528:DC%2BC2cXhs1SisLzL10.1007/s13365-014-0279-x252279304268390 BarcoAOrlandoSStroffoliniGCorrelations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disordersJ Neurovirol202210.1007/s13365-021-01047-y35044644 Guha D, Mukerji SS, Chettimada S et al (2019) Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy. AIDS 33(4):615–625. https://doi.org/10.1097/QAD.0000000000002121 VassalloMFabreRDurantJA decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replicationJ Neurovirol20172322162251:CAS:528:DC%2BC28XhvVertL%2FK10.1007/s13365-016-0490-z27815816 CysiqueLACasalettoKBHeatonRKReliably Measuring Cognitive Change in the Era of Chronic HIV Infection and Chronic HIV-Associated Neurocognitive DisordersCurr Top Behav Neurosci2021502712981:CAS:528:DC%2BB3sXisVCnsLk%3D10.1007/7854_2019_11631559600 Hammond ER, Crum RM, Treisman GJ et al (2016) CHARTER Group. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol 22(4):479–87. https://doi.org/10.1007/s13365-015-0416-1 Boehnke SE, Robertson EL, Armitage-Brown B et al (2020) The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys. Alzheimers Dement (Amst) 12(1):e12069. https://doi.org/10.1002/dad2.12069 Yilmaz A, Verhofstede C, D'Avolio A et al (2010) Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 55(5):590–6. https://doi.org/10.1097/QAI.0b013e3181f5b3d1 Mielke MM, Syrjanen JA, Blennow K et al (2019) Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. Neurology 93(3):e252–e260. https://doi.org/10.1212/WNL.0000000000007767 CiccarelliNFabbianiMDi GiambenedettoSEfavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patientsNeurology20117616140314091:CAS:528:DC%2BC3MXkvValtb0%3D10.1212/WNL.0b013e31821670fb21502598 Kelly KM, Beck SE, Metcalf Pate KA et al (2013) Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain. AIDS 27(18):F21–8. https://doi.org/10.1097/QAD.0000000000000074 Valcour VG, Rubin LH, Obasi MU et al (2016) Womenʼs interagency HIV study protocol team. Liver fibrosis linked to cognitive performance in HIV and hepatitis C. J Acquir Immune Defic Syndr 72(3):266–73. https://doi.org/10.1097/QAI.0000000000000957 Martin-BlondelGBrassatDBauerJCCR5 blockade for neuroinflammatory diseases–beyond control of HIVNat Rev Neurol2016122951051:CAS:528:DC%2BC28XhsFOqs7s%3D10.1038/nrneurol.2015.24826782333 Metral M, Nadin I, Locatelli I et al (2020) Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study group, Swiss HIV Cohort Study. How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? HIV Med 21(5):342–348. https://doi.org/10.1111/hiv.12828 ThomasDApovianCMacrophage functions in lean and obese adipose tissueMetabolism2017721201431:CAS:528:DC%2BC2sXnvVyrtbs%3D10.1016/j.metabol.2017.04.005286417795516622 Alford K, Daley S, Banerjee S et al (2021) Quality of life in people living with HIV-associated neurocognitive disorder: A scoping review study. Plos One 16(5):e0251944. https://doi.org/10.1371/journal.pone.0251944 Haddow LJ, Laverick R, Daskalopoulou M et al (2018) Cognitive impairment in people with hiv in the european region (cipher) study group. Multicenter european prevalence study of neurocognitive impairment and associated factors in hiv positive patients. AIDS Behav 22(5):1573–1583. https://doi.org/10.1007/s10461-017-1683-z VeraJHGarveyLJAllsopJMAlterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopyHIV Clin Trials20121342222271:CAS:528:DC%2BC38XhtFGlur7K10.1310/hct1304-22222849963 BanderaATaramassoLBozziGHIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?Front Aging Neurosci2019111871:CAS:528:DC%2BB3cXmsVGltr0%3D10.3389/fnagi.2019.00187314279556687760 SpencerMEJainAMatteiniASerum levels of the immune activation marker neopterin change with age and gender SH Han (10086_CR24) 2013; 8 10086_CR20 10086_CR21 10086_CR22 A Edén (10086_CR15) 2016; 11 D Thomas (10086_CR43) 2017; 72 AM Anderson (10086_CR2) 2018; 24 N Ciccarelli (10086_CR11) 2011; 76 S Nightingale (10086_CR36) 2014; 13 A Calcagno (10086_CR10) 2018; 15 A Calcagno (10086_CR9) 2016; 22 A Antinori (10086_CR3) 2007; 69 10086_CR12 ME Spencer (10086_CR42) 2010; 65 10086_CR16 10086_CR18 10086_CR1 K Robertson (10086_CR40) 2012; 18 10086_CR52 10086_CR53 10086_CR6 10086_CR8 10086_CR7 TF Msoka (10086_CR34) 2019; 15 10086_CR45 I Motta (10086_CR33) 2017; 22 10086_CR48 M Trunfio (10086_CR46) 2018 10086_CR44 LA Cysique (10086_CR13) 2021; 50 A Bandera (10086_CR4) 2019; 11 I De Benedetto (10086_CR14) 2020; 26 M Vassallo (10086_CR50) 2017; 23 10086_CR37 10086_CR38 LC Ndhlovu (10086_CR35) 2014; 20 J Underwood (10086_CR47) 2015; 29 G Martin-Blondel (10086_CR28) 2016; 12 N Sacktor (10086_CR41) 2018; 24 M Gisslén (10086_CR19) 2015; 22 10086_CR30 S Piconi (10086_CR39) 2016; 29 M Vassallo (10086_CR49) 2013; 19 10086_CR31 A Mondi (10086_CR32) 2015; 70 A Barco (10086_CR5) 2022 JH Vera (10086_CR51) 2012; 13 L Garvey (10086_CR17) 2012; 67 10086_CR23 10086_CR25 10086_CR26 10086_CR27 10086_CR29 |
| References_xml | – reference: GarveyLNelsonMLatchNCNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite studyJ Antimicrob Chemother20126712062121:CAS:528:DC%2BC3MXhs1CqtLrO10.1093/jac/dkr42721987241 – reference: Haddow LJ, Laverick R, Daskalopoulou M et al (2018) Cognitive impairment in people with hiv in the european region (cipher) study group. Multicenter european prevalence study of neurocognitive impairment and associated factors in hiv positive patients. AIDS Behav 22(5):1573–1583. https://doi.org/10.1007/s10461-017-1683-z – reference: Valcour VG, Rubin LH, Obasi MU et al (2016) Womenʼs interagency HIV study protocol team. Liver fibrosis linked to cognitive performance in HIV and hepatitis C. J Acquir Immune Defic Syndr 72(3):266–73. https://doi.org/10.1097/QAI.0000000000000957 – reference: Martin-BlondelGBrassatDBauerJCCR5 blockade for neuroinflammatory diseases–beyond control of HIVNat Rev Neurol2016122951051:CAS:528:DC%2BC28XhsFOqs7s%3D10.1038/nrneurol.2015.24826782333 – reference: MottaIAlliceTRomitoACerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemiaAntivir Ther20172265395431:CAS:528:DC%2BC1MXhtFKjtb0%3D10.3851/IMP314028198350 – reference: CysiqueLACasalettoKBHeatonRKReliably Measuring Cognitive Change in the Era of Chronic HIV Infection and Chronic HIV-Associated Neurocognitive DisordersCurr Top Behav Neurosci2021502712981:CAS:528:DC%2BB3sXisVCnsLk%3D10.1007/7854_2019_11631559600 – reference: Kelly KM, Beck SE, Metcalf Pate KA et al (2013) Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain. AIDS 27(18):F21–8. https://doi.org/10.1097/QAD.0000000000000074 – reference: VassalloMDunaisBDurantJRelevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt studyJ Neurovirol20131943763821:CAS:528:DC%2BC3sXhsVSisb%2FK10.1007/s13365-013-0181-y23846287 – reference: TrunfioMVaiDMontrucchioCDiagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disordersHIV Med201810.1111/hiv.1262229761877 – reference: NightingaleSWinstonALetendreSControversies in HIV-associated neurocognitive disordersLancet Neurol20141311113911511:CAS:528:DC%2BC2cXhslGrs7nK10.1016/S1474-4422(14)70137-1253160204313542 – reference: Trunfio M, Atzori C, Pasquero M et al (2022) Patterns of cerebrospinal fluid alzheimer's dementia biomarkers in people living with HIV: cross-sectional study on associated factors according to viral control, neurological confounders and neurocognition. Viruses 14(4):753. https://doi.org/10.3390/v14040753 – reference: VeraJHGarveyLJAllsopJMAlterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopyHIV Clin Trials20121342222271:CAS:528:DC%2BC38XhtFGlur7K10.1310/hct1304-22222849963 – reference: BanderaATaramassoLBozziGHIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?Front Aging Neurosci2019111871:CAS:528:DC%2BB3cXmsVGltr0%3D10.3389/fnagi.2019.00187314279556687760 – reference: SacktorNSkolaskyRLMoxleyRParoxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trialJ Neurovirol201824116271:CAS:528:DC%2BC2sXhslWjurjE10.1007/s13365-017-0587-z29063516 – reference: Bradshaw D, Gilleece Y, Verma S, Abramowicz I, Bremner S, Perry N (2020) Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. BMJ Open 10(7):e035596. https://doi.org/10.1136/bmjopen-2019-035596 – reference: Lam JO, Hou CE, Hojilla JC et al (2021) Comparison of dementia risk after age 50 between individuals with and without HIV infection. AIDS 35(5):821–828. https://doi.org/10.1097/QAD.0000000000002806 – reference: Boehnke SE, Robertson EL, Armitage-Brown B et al (2020) The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys. Alzheimers Dement (Amst) 12(1):e12069. https://doi.org/10.1002/dad2.12069 – reference: HanSHKimSUKimCOAbnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatmentPLoS ONE2013811:CAS:528:DC%2BC3sXpsFCqtQ%3D%3D10.1371/journal.pone.0052720233009873536776 – reference: Gates TM, Cysique LA, Siefried KJ et al (2016) Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS 30(4):591–600. https://doi.org/10.1097/QAD.0000000000000951 – reference: De BenedettoITrunfioMGuastamacchiaGBonoraSCalcagnoAA review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugsJ Neurovirol202026564265110.1007/s13365-020-00874-932737860 – reference: VassalloMFabreRDurantJA decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replicationJ Neurovirol20172322162251:CAS:528:DC%2BC28XhvVertL%2FK10.1007/s13365-016-0490-z27815816 – reference: BarcoAOrlandoSStroffoliniGCorrelations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disordersJ Neurovirol202210.1007/s13365-021-01047-y35044644 – reference: Yilmaz A, Verhofstede C, D'Avolio A et al (2010) Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 55(5):590–6. https://doi.org/10.1097/QAI.0b013e3181f5b3d1 – reference: EdénAMarcotteTDHeatonRKIncreased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive ImpairmentPLoS ONE20161161:CAS:528:DC%2BC28XhsFGit7jK10.1371/journal.pone.0157160272950364905676 – reference: PiconiSPocaterraDRainoneVMaraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected PatientsSci Rep2016296288531:CAS:528:DC%2BC28XhtFSqt77E10.1038/srep28853 – reference: MsokaTFVan GuilderGPvan FurthMThe effect of HIV infection, antiretroviral therapy on carotid intima-media thickness: A systematic review and meta-analysisLife Sci2019152351:CAS:528:DC%2BC1MXhslGmsLrN10.1016/j.lfs.2019.116851 – reference: Mietelska-Porowska A, Wasik U, Goras M et al (2014) Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci 15(3):4671–713. https://doi.org/10.3390/ijms15034671 – reference: Francisci D, Pirro M, Schiaroli E et al (2019) Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study. Open Forum Infect Dis 6(4):ofz112. https://doi.org/10.1093/ofid/ofz112 – reference: GisslénMPriceRWAndreassonUPlasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional StudyEBioMedicine201522313514010.1016/j.ebiom.2015.11.036 – reference: Pérez-Valero I, Pasquau J, Rubio R et al (2018) GESIDA 7011 Study Group members. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. J Antimicrob Chemother 73(9):2444–2451. https://doi.org/10.1093/jac/dky212 – reference: RobertsonKLinerJMeekerRBAntiretroviral neurotoxicityJ Neurovirol20121853883991:CAS:528:DC%2BC38XhsVyiu7fM10.1007/s13365-012-0120-3228112643581315 – reference: UnderwoodJRobertsonKRWinstonACould antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?AIDS20152932532611:CAS:528:DC%2BC2MXisl2nsLo%3D10.1097/QAD.000000000000053825426811 – reference: AndersonAMEasleyKAKasherNNeurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapyJ Neurovirol20182466957011:CAS:528:DC%2BC1cXhsFSqtLbF10.1007/s13365-018-0664-y301055026279552 – reference: Yu X, Kuo YF, Raji MA et al (2023) Dementias Among Older Males and Females in the U.S. Medicare System With and Without HIV. J Acquir Immune Defic Syndr 93(2):107–115. https://doi.org/10.1097/QAI.0000000000003184 – reference: CiccarelliNFabbianiMDi GiambenedettoSEfavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patientsNeurology20117616140314091:CAS:528:DC%2BC3MXkvValtb0%3D10.1212/WNL.0b013e31821670fb21502598 – reference: CalcagnoAAtzoriCRomitoABlood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patientsJ Neurovirol201622188921:CAS:528:DC%2BC2MXhtlelsLnO10.1007/s13365-015-0371-x26246357 – reference: Guha D, Mukerji SS, Chettimada S et al (2019) Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy. AIDS 33(4):615–625. https://doi.org/10.1097/QAD.0000000000002121 – reference: Nweke M, Mshunqane N, Govender N, Akinpelu AO, Ukwuoma M (2022) Impact of HIV-associated cognitive impairment on functional independence, frailty and quality of life in the modern era: a meta-analysis. Sci Rep 12(1):6470. https://doi.org/10.1038/s41598-022-10474-8. Erratum in: Sci Rep 12(1):10339. – reference: Mielke MM, Syrjanen JA, Blennow K et al (2019) Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. Neurology 93(3):e252–e260. https://doi.org/10.1212/WNL.0000000000007767 – reference: ThomasDApovianCMacrophage functions in lean and obese adipose tissueMetabolism2017721201431:CAS:528:DC%2BC2sXnvVyrtbs%3D10.1016/j.metabol.2017.04.005286417795516622 – reference: AntinoriAArendtGBeckerJTUpdated research nosology for HIV-associated neurocognitive disordersNeurology20076918178917991:STN:280:DC%2BD2snktFyqsQ%3D%3D10.1212/01.WNL.0000287431.88658.8b17914061 – reference: Metral M, Nadin I, Locatelli I et al (2020) Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study group, Swiss HIV Cohort Study. How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? HIV Med 21(5):342–348. https://doi.org/10.1111/hiv.12828 – reference: NdhlovuLCUmakiTChewGMTreatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)J Neurovirol20142065715821:CAS:528:DC%2BC2cXhs1SisLzL10.1007/s13365-014-0279-x252279304268390 – reference: Ciccarelli N, Fabbiani M, Grima P et al (2014) Liver fibrosis is associated with cognitive impairment in HIV-positive patients. J Int AIDS Soc 17(4 Suppl 3):19722. https://doi.org/10.7448/IAS.17.4.19722 – reference: Bobrow K, Xia F, Hoang T, Valcour V, Yaffe K (2020) HIV and risk of dementia in older veterans. AIDS 34(11):1673–1679. https://doi.org/10.1097/QAD.0000000000002597 – reference: Alford K, Daley S, Banerjee S et al (2021) Quality of life in people living with HIV-associated neurocognitive disorder: A scoping review study. Plos One 16(5):e0251944. https://doi.org/10.1371/journal.pone.0251944 – reference: SpencerMEJainAMatteiniASerum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fatJ Gerontol A Biol Sci Med Sci20106588588651:CAS:528:DC%2BC3cXptFGntrY%3D10.1093/gerona/glq06620478905 – reference: Gonzalez EO, Boix V, Deltoro MG et al (2014) The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients. J Int AIDS Soc 17(4 Suppl 3):19643. https://doi.org/10.7448/IAS.17.4.19643 – reference: Trunfio M, Rugge W, Mighetto L et al (2020) Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. AIDS 34(13):1899–1906. https://doi.org/10.1097/QAD.0000000000002601 – reference: Hammond ER, Crum RM, Treisman GJ et al (2016) CHARTER Group. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol 22(4):479–87. https://doi.org/10.1007/s13365-015-0416-1 – reference: MondiAFabbianiMCiccarelliNEfficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot studyJ Antimicrob Chemother2015706184318491:CAS:528:DC%2BC2MXhsFaiu7bP10.1093/jac/dkv03725885326 – reference: CalcagnoABarcoATrunfioMBonoraSCNS-Targeted Antiretroviral Strategies: When Are They Needed and What to ChooseCurr HIV/AIDS Rep2018151849110.1007/s11904-018-0375-229363025 – reference: Lemoine M, Assoumou L, De Wit S et al (2019) ANRS-ECHAM Group. Diagnostic accuracy of noninvasive markers of steatosis, nash, and liver fibrosis in hiv-monoinfected individuals at risk of nonalcoholic fatty liver disease (nafld): results from the echam study. J Acquir Immune Defic Syndr 80(4):e86-e94. https://doi.org/10.1097/QAI.0000000000001936 – ident: 10086_CR38 doi: 10.1093/jac/dky212 – ident: 10086_CR27 doi: 10.1097/QAI.0000000000001936 – volume: 15 issue: 235 year: 2019 ident: 10086_CR34 publication-title: Life Sci doi: 10.1016/j.lfs.2019.116851 – ident: 10086_CR30 doi: 10.1212/WNL.0000000000007767 – ident: 10086_CR6 doi: 10.1097/QAD.0000000000002597 – volume: 18 start-page: 388 issue: 5 year: 2012 ident: 10086_CR40 publication-title: J Neurovirol doi: 10.1007/s13365-012-0120-3 – volume: 72 start-page: 120 year: 2017 ident: 10086_CR43 publication-title: Metabolism doi: 10.1016/j.metabol.2017.04.005 – volume: 15 start-page: 84 issue: 1 year: 2018 ident: 10086_CR10 publication-title: Curr HIV/AIDS Rep doi: 10.1007/s11904-018-0375-2 – ident: 10086_CR8 doi: 10.1136/bmjopen-2019-035596 – ident: 10086_CR1 doi: 10.1371/journal.pone.0251944 – volume: 69 start-page: 1789 issue: 18 year: 2007 ident: 10086_CR3 publication-title: Neurology doi: 10.1212/01.WNL.0000287431.88658.8b – volume: 76 start-page: 1403 issue: 16 year: 2011 ident: 10086_CR11 publication-title: Neurology doi: 10.1212/WNL.0b013e31821670fb – volume: 23 start-page: 216 issue: 2 year: 2017 ident: 10086_CR50 publication-title: J Neurovirol doi: 10.1007/s13365-016-0490-z – ident: 10086_CR23 doi: 10.1007/s13365-015-0416-1 – ident: 10086_CR45 doi: 10.1097/QAD.0000000000002601 – ident: 10086_CR53 doi: 10.1097/QAI.0000000000003184 – volume: 29 start-page: 28853 issue: 6 year: 2016 ident: 10086_CR39 publication-title: Sci Rep doi: 10.1038/srep28853 – ident: 10086_CR7 doi: 10.1002/dad2.12069 – volume: 22 start-page: 88 issue: 1 year: 2016 ident: 10086_CR9 publication-title: J Neurovirol doi: 10.1007/s13365-015-0371-x – year: 2022 ident: 10086_CR5 publication-title: J Neurovirol doi: 10.1007/s13365-021-01047-y – volume: 22 start-page: 539 issue: 6 year: 2017 ident: 10086_CR33 publication-title: Antivir Ther doi: 10.3851/IMP3140 – ident: 10086_CR31 doi: 10.3390/ijms15034671 – ident: 10086_CR21 doi: 10.1097/QAD.0000000000002121 – volume: 70 start-page: 1843 issue: 6 year: 2015 ident: 10086_CR32 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkv037 – ident: 10086_CR44 doi: 10.3390/v14040753 – ident: 10086_CR22 doi: 10.1007/s10461-017-1683-z – ident: 10086_CR20 doi: 10.7448/IAS.17.4.19643 – ident: 10086_CR48 doi: 10.1097/QAI.0000000000000957 – ident: 10086_CR29 doi: 10.1111/hiv.12828 – volume: 22 start-page: 135 issue: 3 year: 2015 ident: 10086_CR19 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2015.11.036 – volume: 11 issue: 6 year: 2016 ident: 10086_CR15 publication-title: PLoS ONE doi: 10.1371/journal.pone.0157160 – ident: 10086_CR26 doi: 10.1097/QAD.0000000000002806 – volume: 24 start-page: 695 issue: 6 year: 2018 ident: 10086_CR2 publication-title: J Neurovirol doi: 10.1007/s13365-018-0664-y – volume: 26 start-page: 642 issue: 5 year: 2020 ident: 10086_CR14 publication-title: J Neurovirol doi: 10.1007/s13365-020-00874-9 – volume: 19 start-page: 376 issue: 4 year: 2013 ident: 10086_CR49 publication-title: J Neurovirol doi: 10.1007/s13365-013-0181-y – volume: 24 start-page: 16 issue: 1 year: 2018 ident: 10086_CR41 publication-title: J Neurovirol doi: 10.1007/s13365-017-0587-z – ident: 10086_CR16 doi: 10.1093/ofid/ofz112 – ident: 10086_CR52 doi: 10.1097/QAI.0b013e3181f5b3d1 – volume: 12 start-page: 95 issue: 2 year: 2016 ident: 10086_CR28 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2015.248 – volume: 20 start-page: 571 issue: 6 year: 2014 ident: 10086_CR35 publication-title: J Neurovirol doi: 10.1007/s13365-014-0279-x – ident: 10086_CR37 doi: 10.1038/s41598-022-10474-8 – ident: 10086_CR12 doi: 10.7448/IAS.17.4.19722 – volume: 11 start-page: 187 year: 2019 ident: 10086_CR4 publication-title: Front Aging Neurosci doi: 10.3389/fnagi.2019.00187 – ident: 10086_CR18 doi: 10.1097/QAD.0000000000000951 – volume: 50 start-page: 271 year: 2021 ident: 10086_CR13 publication-title: Curr Top Behav Neurosci doi: 10.1007/7854_2019_116 – year: 2018 ident: 10086_CR46 publication-title: HIV Med doi: 10.1111/hiv.12622 – volume: 13 start-page: 222 issue: 4 year: 2012 ident: 10086_CR51 publication-title: HIV Clin Trials doi: 10.1310/hct1304-222 – volume: 29 start-page: 253 issue: 3 year: 2015 ident: 10086_CR47 publication-title: AIDS doi: 10.1097/QAD.0000000000000538 – ident: 10086_CR25 doi: 10.1097/QAD.0000000000000074 – volume: 65 start-page: 858 issue: 8 year: 2010 ident: 10086_CR42 publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/glq066 – volume: 8 issue: 1 year: 2013 ident: 10086_CR24 publication-title: PLoS ONE doi: 10.1371/journal.pone.0052720 – volume: 67 start-page: 206 issue: 1 year: 2012 ident: 10086_CR17 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr427 – volume: 13 start-page: 1139 issue: 11 year: 2014 ident: 10086_CR36 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70137-1 |
| SSID | ssj0044400 |
| Score | 2.3536105 |
| Snippet | The prevalence of neurocognitive impairment in people living with HIV is estimated between 30 and 50%. The pathogenesis of HIV-associated neurocognitive... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 551 |
| SubjectTerms | Adult Antiretroviral drugs Biomarkers Biomarkers - cerebrospinal fluid Biomedical and Life Sciences Biomedicine Carotid Intima-Media Thickness Cell Biology Darunavir Female HIV HIV Infections - complications HIV Infections - drug therapy Human immunodeficiency virus Humans Immunology Liver Male Middle Aged Neopterin - cerebrospinal fluid Neopterin - therapeutic use Neurocognitive Disorders - chemically induced Neurocognitive Disorders - diagnostic imaging Neurocognitive Disorders - epidemiology Neurosciences Neurotoxicity Pharmacology/Toxicology Prospective Studies Viral Load Virology |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDI9gvPCC-KZsoCChvXARbdJr0icEE6cbGug03dC9VUnajopdu117EuMP4-_DTr90TOy1dd1WdmI7tn8m5C14HIbnVjHfWgEBiq-ZjtOIGe4ra1ITBC7R_vVbND8Lv6ymq-7Are7KKvs90W3UaWXxjPw9B7smAzCe0YfLK4ZTozC72o3QuEvuIXQZBl9yNQRcYRi6FhQwmZIFKva7ppm2dQ7iAAikOVZmgVvP5K5huuFt3iya_Cdz6gzS7CF50HmS9GMr-kfkTlY-JoeLFor6ekKXY2dVPaGHdDGCVF8_IX_atoKaFiU9yjYQGeMAEWQ4u9gW6YSeYMEG1WVKj8umWGvmekwYlsf_xO2RfiqqNdb2bByPRYvPWlM82KXz4-9Md4LPUuoQQIZCJdojftb0FPhX6-I30DQV1fQEGTvqpvpVWLrsy-DpaXaOcwiekrPZ5-XRnHUzHJgN5bRhXHNfZjzOo9wIsIPTFCfMTKM01GlgrBZWCMNVDnrBo9jYWKnQxCCWTNnIhEI8I3tlVWYvCA1EoEMRxSrPLchO6dSPfKkziMg0XMs9EvQCTGwHcI5zNi6SEZoZhZ4A98QJPZEeeTc8c9nCe9xKfdDrRdIt9ToZFdMjb4bbsEgx86LLrNoCjVJTjt5U7JHnrRoNrxMyxmwqPK12FGwgQADw3Ttl8cMBgcOLJUJAemTS6-L4Xf__jZe3_8Y-uc_dusCanQOy12y22SvwvBrz2i2vvzO6La8 priority: 102 providerName: ProQuest |
| Title | Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen |
| URI | https://link.springer.com/article/10.1007/s11481-023-10086-7 https://www.ncbi.nlm.nih.gov/pubmed/37906406 https://www.proquest.com/docview/2910719766 https://www.proquest.com/docview/2885202189 https://pubmed.ncbi.nlm.nih.gov/PMC10770227 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELbY3QsXxJvAUhkJ7YVaSpyHnWO3aunCsqqqFpVTZDsORGwT1KQSyw_j9zF2HlVZQOJUKZlMWs3Ynul88w1CryHikDRTnLhK-ZCguIKIOI2IpC5XMpWeZwvtH66i2Sp4tw7XbVNY1aHdu5Kk3an3zW4QuUPqSw2WCgJxwo7QSQi5u_HrFR11-28QBLbxBA5KRjweu22rzJ91HB5Ht2LM21DJ3-ql9hia3kf32vgRjxqDP0B3dPEQnc0bAuqbIV7u-6mqIT7D8z019c0j9LNpJqhwXuCx3kI-bMaGGIXT612eDvGlgWlgUaT4oqjzjSC2s4QYUPxXsyni87zcGETP1uqYN6ysFTZ_5-LZxUciWnPrFFvejx6ehDuezwovQH-5yX-ATF1igS-NYitdl99zhZcd-B0v9GczfeAxWk0ny_GMtJMbiApYWBMqqMs0jbMokz6cfmFq5sqEURqI1JNK-Mr3JeUZeAONYqlizgMZg1k0V5EMfP8JOi7KQj9D2PM9EfhRzLNMge24SN3IZUJDHibgWuYgrzNgolpaczNd4zrZEzIboyegPbFGT5iD3vTPfGtIPf4pfdr5RdIu8CqhEGYxD2K5yEGv-tuwNE29RRS63IEM58Y_wQcd9LRxo_51PotNDRWe5gcO1gsY2u_DO0X-xdJ_w4uZIX500LDzxf33-vvPeP5_4i_QXWrXiUHunKLjervTLyH-quUAHbE1G6CT0dtP7yfweT65mi_g6jgaD-xS_AU1My92 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V6QEuiDeGAosEvZAV9tqx1weEaGmU0DSKohT1ZtbrNVg0dokdQfhRHPl9zKztRKGit17t9djWzM5jZ-YbQl6CxxHzVAlmK-VCgGJLJsPEZzG3hYqT2HFMov1k7A9OvY9nvbMd8rvthcGyylYnGkWdFArPyN9wsGuBA8bTf3fxneHUKMyutiM0arE41qsfELKVb4cfgL-vOO8fzQ4HrJkqwJQX9CrGJbcDzcPUT2MXNHMvwZknPT_xZOLESrrKdWMuUvhS7oexCoXw4hBMmxbKjz08AAWVv-u54Cp0yO7B0XgybXW_53mm6QWMdMAcEdpNm07drAeRB4TuHGvBIJBgwbYpvOTfXi7T_CdXa0xg_za51fiu9H0tbHfIjs7vkv1JDX696tLZpper7NJ9OtnAYq_ukT91I0NJs5we6gXE4jiyBAn2z5dZ0qUjLBGhMk_oMK-yuWSmq4VhQf43VMj0ICvmWE20MDQmNSJsSfEomQ6Gn5hsRE0n1GCOrEujaIsxWtIp0C_m2S9YUxVU0hESNqur4mem6KwtvKdT_QUnH9wnp9fC3wekkxe5fkSo4zoS-ByKNFXAOyET27cDqSEGlHAttYjTMjBSDaQ6TvY4jzZg0Mj0CKhHhulRYJHX62cuakCRK1fvtXIRNcqljDZbwSIv1rdBLWCuR-a6WMIaIXoc_bfQIg9rMVq_zg1CzN_C02JLwNYLEHJ8-06efTXQ4_DiAEEnLdJtZXHzXf__jcdX_8ZzcmMwOxlFo-H4-Am5yc0ewYqhPdKpFkv9FPy-Kn7WbDZKPl_3_v4Le4ZrwA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF5BkRAXxBtDgUVCvZBV7fVrfSyFKIFQRVWCerP2YYNFY1exI1F-GL-PmfUjhAISV3t2bGtmd2c933xDyCuIOBTPtWCu1j4cUFzJZGIiprgrtDLK82yi_eNJNFkG78_Cs1-q-C3avU9JtjUNyNJUNocXJj_cFr5BFA_HYI64KgjKWXyd3IDl2ENQ15If9WtxEAS2CAU2zZh5InG7spk_69jdmq7Em1dhk7_lTu2WNL5DbnexJD1qjX-XXMvKe-Rg3pJRX47oYltbVY_oAZ1vaaov75MfbWFBTYuSHmdrOBtjCxFUOD7fFGZEZwjZoLI0dFo2xUoyW2XCECD_FRdI-qaoVojuWVsd85ahtab4a5dOpp-Y7EyfGWo5QAaoEu05P2t6CvqrVfEdZJqKSjpDxVa6qb4Vmi56IDw9zT5jJ4IHZDl-tziesK6LA9NBHDaMS-7GGU_yKFc-7IShwR4zYWQCaTylpa99X3GRg2fwKFE6ESJQCZglEzpSge8_JHtlVWaPCQUDy8CPEpHnGmwnpHEjN5YZnMkkXMsd4vUGTHVHcY6dNs7TLTkzGj0F7ak1eho75PUw5qIl-Pin9H7vF2k32euUQ8gVexDXRQ55OdyGaYq5F1lm1QZkhAg5xlOJQx61bjQ8zo8TzKfCaLHjYIMAUoDv3imLL5YKHB4cIwmkQ0a9L27f6--f8eT_xF-Qm_O343Q2PfnwlNzidsogoGef7DXrTfYMwrJGPbcz7yc1XDGz |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+Cerebrospinal+Fluid%2C+Liver+and+Intima-media-thickness+Biomarkers+in+Patients+with+HIV-associated+Neurocognitive+Disorders+Randomized+to+a+Less+Neurotoxic+Treatment+Regimen&rft.jtitle=Journal+of+neuroimmune+pharmacology&rft.au=Stroffolini%2C+Giacomo&rft.au=Lazzaro%2C+Alessandro&rft.au=Barco%2C+Ambra&rft.au=Pirriatore%2C+Veronica&rft.date=2023-12-01&rft.pub=Springer+US&rft.issn=1557-1890&rft.eissn=1557-1904&rft.volume=18&rft.issue=4&rft.spage=551&rft.epage=562&rft_id=info:doi/10.1007%2Fs11481-023-10086-7&rft.externalDocID=10_1007_s11481_023_10086_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-1890&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-1890&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-1890&client=summon |